{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:47Z","timestamp":1740107027215,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00432-018-2633-5","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T03:56:46Z","timestamp":1522900606000},"page":"1173-1183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-5772","authenticated-orcid":false,"given":"Frank","family":"Heinzelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich Wilhelm","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Engelhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annerose","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imme","family":"Haubitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hellmut","family":"Ottinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,5]]},"reference":[{"key":"2633_CR1","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ et al (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:5165\u20135169. https:\/\/doi.org\/10.1200\/JCO.2008.16.0283","journal-title":"J Clin Oncol"},{"key":"2633_CR2","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","volume":"31","author":"P Armand","year":"2013","unstructured":"Armand P et al (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31:4199\u20134206. https:\/\/doi.org\/10.1200\/jco.2012.48.3685","journal-title":"J Clin Oncol"},{"key":"2633_CR3","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","volume":"15","author":"Y Bastion","year":"1997","unstructured":"Bastion Y et al (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587\u20131594","journal-title":"J Clin Oncol"},{"key":"2633_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo C, Burack WR, Friedberg JW (2015) Transformed follicular non-Hodgkin. lymphoma Blood 125:40\u201347. https:\/\/doi.org\/10.1182\/blood-2014-04-516815","journal-title":"lymphoma Blood"},{"key":"2633_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1046\/j.1365-2141.2001.02705.x","volume":"113","author":"CI Chen","year":"2001","unstructured":"Chen CI, Crump M, Tsang R, Stewart AK, Keating A (2001) Autotransplants for histologically transformed follicular non-Hodgkin\u2019s lymphoma. Br J Haematol 113:202\u2013208","journal-title":"Br J Haematol"},{"key":"2633_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"2633_CR7","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3109\/10428194.2010.497981","volume":"51","author":"A Clavert","year":"2010","unstructured":"Clavert A et al (2010) Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 51:1502\u20131508. https:\/\/doi.org\/10.3109\/10428194.2010.497981 [doi]","journal-title":"Leuk Lymphoma"},{"key":"2633_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","volume":"154","author":"MS Czuczman","year":"2011","unstructured":"Czuczman MS et al (2011) The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 154:477\u2013481. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08781.x","journal-title":"Br J Haematol"},{"key":"2633_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","volume":"131","author":"RT Doocey","year":"2005","unstructured":"Doocey RT et al (2005) Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131:223\u2013230. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05755.x","journal-title":"Br J Haematol"},{"key":"2633_CR10","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.314","author":"AS Freedman","year":"2005","unstructured":"Freedman AS (2005) Biology and management of histologic transformation of indolent lymphoma Hematol Educ Progr Am Soc Hematol Am Soc Hematol Educ Progr. https:\/\/doi.org\/10.1182\/asheducation-2005.1.314","journal-title":"Hematol Educ Progr Am Soc Hematol Am Soc Hematol Educ Progr"},{"key":"2633_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW et al (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26:204\u2013210. https:\/\/doi.org\/10.1200\/JCO.2007.12.5070","journal-title":"J Clin Oncol"},{"key":"2633_CR12","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1080\/10428190802270902","volume":"49","author":"M Hamadani","year":"2008","unstructured":"Hamadani M et al (2008) Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma 49:1893\u20131898. https:\/\/doi.org\/10.1080\/10428190802270902","journal-title":"Leuk Lymphoma"},{"key":"2633_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bmt.2015.348","volume":"51","author":"F Heinzelmann","year":"2016","unstructured":"Heinzelmann F et al (2016) Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. Bone Marrow Transplant 51:654\u2013662. https:\/\/doi.org\/10.1038\/bmt.2015.348","journal-title":"Bone Marrow Transplant"},{"key":"2633_CR14","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med 311:1471\u20131475","journal-title":"N Engl J Med"},{"key":"2633_CR15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","volume":"77","author":"RJ Jones","year":"1991","unstructured":"Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649\u2013653","journal-title":"Blood"},{"key":"2633_CR16","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF et al (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide and rituximab. Blood 111:5530\u20135536","journal-title":"Blood"},{"key":"2633_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood-2015-01-622084","volume":"126","author":"J Kuruvilla","year":"2015","unstructured":"Kuruvilla J et al (2015) Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood 126:733\u2013738. https:\/\/doi.org\/10.1182\/blood-2015-01-622084","journal-title":"Blood"},{"key":"2633_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V91.1.331.331_331_339","volume":"91","author":"BM Leonard","year":"1998","unstructured":"Leonard BM, Hetu F, Busque L, Gyger M, Belanger R, Perreault C, Roy DC (1998) Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 91:331\u2013339","journal-title":"Blood"},{"key":"2633_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/annonc\/mdu537","volume":"26","author":"C Madsen","year":"2015","unstructured":"Madsen C et al (2015) Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. Ann Oncol 26:393\u2013399. https:\/\/doi.org\/10.1093\/annonc\/mdu537","journal-title":"Ann Oncol"},{"key":"2633_CR20","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S et al (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426\u20132433. https:\/\/doi.org\/10.1200\/JCO.2006.09.3260","journal-title":"J Clin Oncol"},{"key":"2633_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107:265\u2013276","journal-title":"Blood"},{"key":"2633_CR22","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"2633_CR23","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/blood.V92.10.3515.422k49_3515_3520","volume":"92","author":"EW Petersdorf","year":"1998","unstructured":"Petersdorf EW et al (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92:3515\u20133520","journal-title":"Blood"},{"key":"2633_CR24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/bmt.2008.220","volume":"42","author":"KM Ramadan","year":"2008","unstructured":"Ramadan KM et al (2008) Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 42:601\u2013608. https:\/\/doi.org\/10.1038\/bmt.2008.220","journal-title":"Bone Marrow Transplant"},{"key":"2633_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","volume":"26","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR et al (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:211\u2013217","journal-title":"J Clin Oncol"},{"key":"2633_CR26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1158\/1055-9965.EPI-05-0958","volume":"15","author":"S Sandin","year":"2006","unstructured":"Sandin S, Hjalgrim H, Glimelius B, Rostgaard K, Pukkala E, Askling J (2006) Incidence of non-Hodgkin\u2019s lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiol Biomark Prev 15:1295\u20131300","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2633_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM et al (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204\u2013217","journal-title":"Am J Med"},{"key":"2633_CR28","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.23375","volume":"112","author":"M Sorror","year":"2008","unstructured":"Sorror M et al (2008) Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112:1992\u20132001","journal-title":"Cancer"},{"key":"2633_CR29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","volume":"27","author":"KJ Thomson","year":"2009","unstructured":"Thomson KJ et al (2009) Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 27:426\u2013432. https:\/\/doi.org\/10.1200\/JCO.2008.17.3328","journal-title":"J Clin Oncol"},{"key":"2633_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","volume":"19","author":"KW Besien van","year":"1997","unstructured":"van Besien KW et al (1997) Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19:977\u2013982","journal-title":"Bone Marrow Transplant"},{"key":"2633_CR31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bbmt.2009.01.012","volume":"15","author":"K Besien van","year":"2009","unstructured":"van Besien K et al (2009) Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 15:554\u2013563","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"key":"2633_CR32","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJ Kampen van","year":"2011","unstructured":"van Kampen RJ et al (2011) Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29:1342\u20131348. https:\/\/doi.org\/10.1200\/jco.2010.30.2596","journal-title":"J Clin Oncol"},{"key":"2633_CR33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","volume":"31","author":"D Villa","year":"2013","unstructured":"Villa D et al (2013) Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol 31:1164\u20131171. https:\/\/doi.org\/10.1200\/jco.2012.44.0693","journal-title":"J Clin Oncol"},{"key":"2633_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND et al (2015) Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 126:851\u2013857. https:\/\/doi.org\/10.1182\/blood-2015-01-621375","journal-title":"Blood"},{"key":"2633_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","volume":"19","author":"CD Williams","year":"2001","unstructured":"Williams CD et al (2001) High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin\u2019s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19:727\u2013735","journal-title":"J Clin Oncol"},{"key":"2633_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.bbmt.2014.03.014","volume":"20","author":"B Wirk","year":"2014","unstructured":"Wirk B et al (2014) Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 20:951\u2013959. https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.014","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"key":"2633_CR37","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE et al (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:3262\u20133269","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2633-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2633-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2633-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:24:47Z","timestamp":1571012687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2633-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,5]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2633"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2633-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2018,4,5]]},"assertion":[{"value":"7 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}